Compare Kroger Co (KR) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kroger Co vs Medpace Holdings Inc — how do they compare? Kroger Co trades at $56.1 (market cap $34.46B), while Medpace Holdings Inc trades at $601.1 (market cap $16.90B). The key difference: Kroger Co is far larger — about 2× Medpace Holdings Inc's market cap, and Kroger Co pays a 2.56% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| KR | MEDP | |
|---|---|---|
Market Cap | $34.46B | $16.90B |
Sector | Consumer Staples | Technology |
52-Week High | $75.60 | $620.59 |
52-Week Low | $55.53 | $393.42 |
Enterprise Value | $54.56B | $16.52B |
Dividend Yield | 2.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kroger (KR) trades at $56.15, down 0.58% on the day, reflecting recent market pressure. The stock shows mixed signals with a bearish technical outlook but solid fundamentals including a low P/S ratio of 0.24 and consistent dividend payments. Recent earnings saw a Q1 2026 miss but beats in prior quarters, while analyst consensus remains positive with a $68.25 price target. Cash flow from operations remains strong at $5.79B in 2025, supporting ongoing investments in e-commerce and digital initiatives.
The outlook for KR is cautiously optimistic. Valuation appears reasonable relative to sales, and dividend income provides stability. However, near-term risks include competitive pressures in grocery retail, margin compression from inflation, and technical bearish signals. Investors should weigh strong cash generation against earnings volatility and debt levels that have risen to 30.23% of assets in 2025.
MEDP trades at $600.00, down 0.4% on the day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $4.25, and raised full-year guidance. Revenue growth is robust, with 2026 projected at $2.8 billion, though valuation multiples like a P/E of 35.58 and P/B of 38.95 are elevated. Net cash flow is expected to turn positive in 2026, and institutional activity is mixed, with some funds increasing stakes while others trim positions.
Outlook is positive due to earnings momentum and record bookings, but risks include high valuation sensitivity and a shareholder lawsuit investigation. Analyst consensus is a $599.57 price target with a 'Hold' bias, suggesting limited near-term upside from current levels amid growth-priced expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kroger Co
Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
